A study of the combination of oxaliplatin, capecitabine, and herceptin (trastuzumab) and chemoradiotherapy in the adjuvant setting in operated patients with HER2+gastric or gastro-esophageal junction cancer (TOXAG study).

被引：5
|
作者：
Abali, Huseyin
Yalcin, Suayib
Onal, Huseyin Cem
Dane, Faysal
Oksuzoglu, Berna
Ozdemir, Nuriye
Mertsoylu, Huseyin
Artac, Mehmet
Camci, Celalettin
Karabulut, Bulent
Basal, Fatma Bugdayci
Budakoglu, Burcin
Sendur, Mehmet Ali Nahit
Goktas, Burce
Ozdener, Fatih
Calisgan, Arzu
机构：
[1] Acibadem Univ, Adana, Turkey
[2] Hacettepe Univ, Ankara, Turkey
[3] Baskent Univ, Radiat Oncol, Adana, Turkey
[4] Marmara Univ, Istanbul, Turkey
[5] Dr Abdurrahman Yurtaslan Ankara Onkol Training &, Ankara, Turkey
[6] Ankara Numune Training & Res Hosp, Ankara, Turkey
[7] Baskent Univ, Adana, Turkey
[8] Necmettin Erbakan Univ, Meram Sch Med, Konya, Turkey
[9] Gaziantep Univ, Gaziantep, Turkey
[10] Ege Univ, Izmir, Turkey
[11] Yildirim Beyazit Univ, Fac Med, Dept Med Oncol, Ankara, Turkey
[12] Roche Pharmaceut, Istanbul, Turkey
[13] Medstats Consulting, Istanbul, Turkey
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2016年 / 34卷 / 04期
关键词：
D O I：
10.1200/jco.2016.34.4_suppl.tps182
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
TPS182
引用
收藏
页数：1
相关论文
共 50 条
  • [41] Phase II study of telatinib (T) in combination with capecitabine (X) and cisplatin (P) as first-line treatment in patients (pts) with advanced cancer of the stomach (G) or gastro-esophageal junction (GEI).
    Ko, A. H.
    Tabernero, J.
    Garcia De Paredes, M.
    Rivera, F.
    Schnell, F. M.
    Baker, J. S.
    Phan, A. T.
    Alsina, M.
    Patel, K.
    Ajani, J. A.
    JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)
  • [42] Correction to: Phase II study to evaluate the efficacy of Trastuzumab in combination with Capecitabine and Oxaliplatin in first-line treatment of HER2-positive advanced gastric cancer: HERXO trial
    Fernando Rivera
    C. Romero
    P. Jimenez-Fonseca
    M. Izquierdo-Manuel
    A. Salud
    E. Martínez
    M. Jorge
    V. Arrazubi
    J. C. Méndez
    P. García-Alfonso
    M. Reboredo
    J. Barriuso
    N. Muñoz-Unceta
    R. Jimeno
    C. López
    Cancer Chemotherapy and Pharmacology, 2019, 84 : 1365 - 1365
  • [43] Central Nervous System metastastasis in gastric or gastro-esophageal junction cancer, correlation with human epidermal growth factor 2 (HER-2) status
    Mordenti, P.
    Seghini, P.
    Di Nunzio, C.
    Michieletti, E.
    Stroppa, E. M.
    Zangrandi, A.
    Cavanna, L.
    ANNALS OF ONCOLOGY, 2015, 26 : 99 - 99
  • [44] Adjuvant capecitabine plus oxaliplatin after D2 gastrectomy in Japanese patients with gastric cancer: a phase II study
    Nozomu Fuse
    Hideaki Bando
    Keisho Chin
    Seiji Ito
    Takaki Yoshikawa
    Akira Tsuburaya
    Masanori Terashima
    Yoshiyuki Kawashima
    Tetsu Fukunaga
    Masahiro Gotoh
    Yasunori Emi
    Kazuhiro Yoshida
    Eiji Oki
    Seiji Takahashi
    Hiroshi Kuriki
    Kumi Sato
    Mitsuru Sasako
    Gastric Cancer, 2017, 20 : 332 - 340
  • [45] Adjuvant capecitabine plus oxaliplatin after D2 gastrectomy in Japanese patients with gastric cancer: a phase II study
    Fuse, Nozomu
    Bando, Hideaki
    Chin, Keisho
    Ito, Seiji
    Yoshikawa, Takaki
    Tsuburaya, Akira
    Terashima, Masanori
    Kawashima, Yoshiyuki
    Fukunaga, Tetsu
    Gotoh, Masahiro
    Emi, Yasunori
    Yoshida, Kazuhiro
    Oki, Eiji
    Takahashi, Seiji
    Kuriki, Hiroshi
    Sato, Kumi
    Sasako, Mitsuru
    GASTRIC CANCER, 2017, 20 (02) : 332 - 340
  • [46] Trastuzumab: a novel standard option for patients with HER-2-positive advanced gastric or gastro-oesophageal junction cancer
    Okines, Alicia F. C.
    Cunningham, David
    THERAPEUTIC ADVANCES IN GASTROENTEROLOGY, 2012, 5 (05): : 301 - 318
  • [47] Trastuzumab with triple chemotherapy (DOC-T) in patients with advanced gastro-esophageal cancer. A phase I/II study
    Pfeiffer, P.
    Yilmaz, M.
    Baeksgaard, L.
    Schonnemann, K. R.
    Krogh, M.
    Qvortrup, C.
    Bjerregaard, J. K.
    Jensen, H. A.
    Vestermark, L. W.
    EUROPEAN JOURNAL OF CANCER, 2015, 51 : S450 - S451
  • [48] A phase-Ib study of TRK-950 combined with anticancer treatment regimens in patients with gastric and gastro-esophageal junction (GEJ) cancer.
    Cassier, Philippe Alexandre
    Matrana, Marc Ryan
    Hanna, Diana L.
    George, Ben
    Sharma, Sunil
    Kelly, Ronan Joseph
    Okano, Fumiyoshi
    Von Hoff, Daniel D.
    Blay, Jean-Yves
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 : 361 - 361
  • [49] A phase Ib study of nivolumab plus trastuzumab with S-1/capecitabine plus oxaliplatin for HER2 positive advanced gastric cancer (Ni-HIGH study).
    Takahari, Daisuke
    Wakatsuki, Takeru
    Ishizuka, Naoki
    Fukuda, Naoki
    Shoji, Hirokazu
    Hara, Hiroki
    Minashi, Keiko
    Boku, Narikazu
    Yamaguchi, Kensei
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (04)
  • [50] Observational study on adjuvant trastuzumab in HER2-positive early breast cancer patients
    Mustacchi, G.
    Puglisi, F.
    Molino, A. M.
    Crivellari, D.
    Ghiotto, C.
    Ferro, A.
    Brunello, A.
    Saracchini, S.
    Turazza, M.
    Cretella, E.
    Iop, A.
    Malagoli, M.
    Stefani, M.
    FUTURE ONCOLOGY, 2015, 11 (10) : 1493 - 1500
12345